How Long Till Allergy Shots Work? Coping While You Wait for Results

Whether 6 months with no improvement is concerning depends on which phase you're in. If you're still in build-up or just reaching the maintenance dose at 6 months, absence of clinical benefit at that point is completely expected — the immunologic process is still in early stages and most clinical trials show benefit emerging after 6-12 months of maintenance, not initiation. If you've been at a therapeutic maintenance dose for 6 months and still notice zero change — no reduction in rescue medication use, no shorter symptom episodes, no improvement during your allergen's peak season — that is worth raising with your allergist. The AAAAI Practice Parameter suggests that absence of benefit after one full year of maintenance is grounds for reassessment: dose review, allergen mix evaluation, and consideration of whether the initial allergen selection matches your actual clinical triggers.

Yes — continuing antihistamines during the build-up phase of allergy shots is standard of care and does not interfere with the immunologic response of the treatment. A study by Reimers et al. (JACI 2000) confirmed that antihistamine use during SCIT does not impair the development of blocking antibodies or Treg responses. Second-generation, non-sedating antihistamines such as cetirizine, loratadine, or fexofenadine are preferred for daily use during the waiting period. Some allergists recommend taking an antihistamine 30-60 minutes before your injection to reduce the likelihood of a local injection-site reaction, though this is not universally required. Discuss your current antihistamine regimen with your allergist at your next visit — they may have specific preferences for your situation, particularly if you're at a point in build-up where injection-site reactions have been a pattern.

Nasal corticosteroid sprays are the most effective bridge treatment for seasonal allergy symptoms during the SCIT waiting period. Dykewicz et al. (JACI 2020) identify fluticasone propionate, mometasone furoate, and budesonide as first-line options for allergic rhinitis symptom control. Unlike oral corticosteroids, intranasal steroids have minimal systemic absorption and can be used safely alongside SCIT throughout the waiting period. Second-generation antihistamines (cetirizine, fexofenadine) add symptom relief for sneezing, itching, and watery eyes. Decongestants can be used short-term for nasal congestion but are not suitable for long-term use. The important principle is that all standard allergy medications can be continued alongside SCIT — the shots do not require you to stop medications to prove they're working. Your rescue medication use itself becomes a tracking metric: measuring how often you reach for these bridging medications will show early signs of treatment progress before symptoms improve noticeably.

Several objective and subjective milestones indicate treatment is working, even before you consciously feel dramatically better. The most measurable early milestone is reduced rescue antihistamine use — a 20-40% decline in how often you need an antihistamine is detectable within 6 months of maintenance and is one of the first patient-perceivable signs of treatment effect. The next milestone is shorter symptom episodes: instead of a 3-week peak-season flare, you may notice symptoms lasting 1-2 weeks before resolving. Milder peak-season reactions — symptoms that used to require an antihistamine plus decongestant now managed with just an antihistamine — also signal progress. Skin prick test reactivity may begin decreasing between 6-12 months, providing an objective measure your allergist can document. The absence of seasonal symptom worsening during your first treated pollen season — even if not dramatic improvement — is itself considered an early efficacy signal in clinical consensus.

Starting allergy shots outside your relevant pollen season is recommended by most allergists for a practical reason: build-up proceeds more safely when you're not actively exposed to high allergen loads. Patients starting outside peak season have a smoother dose escalation and may perceive earlier benefit during their first exposed season compared to those who start mid-season and must navigate build-up while symptomatic. Per clinical consensus guidelines, initiating SCIT during pollen season — particularly for high-reactivity patients — can require dose modification because allergen challenge combined with injections increases systemic reaction risk. Many practices reduce SCIT doses by approximately 40% during a patient's relevant pollen season (Larenas-Linnemann, Ann Allergy 2012), which effectively slows build-up. Starting before the season allows full-dose escalation before your first allergen exposure, positioning you for a better first treated season.